Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,624 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I results of vinorelbine with concurrent radiotherapy in elderly patients with unresectable, locally advanced non-small-cell lung cancer: West Japan Thoracic Oncology Group (WJTOG3005-DI).
Harada H, Seto T, Igawa S, Tsuya A, Wada M, Kaira K, Naito T, Hayakawa K, Nishimura T, Masuda N, Yamamoto N. Harada H, et al. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1777-82. doi: 10.1016/j.ijrobp.2011.03.037. Epub 2011 May 27. Int J Radiat Oncol Biol Phys. 2012. PMID: 21621337 Clinical Trial.
Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor--tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation.
Imai H, Shukuya T, Takahashi T, Fujiwara S, Mori K, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Kaira K, Murakami H, Harada H, Endo M, Nakajima T, Yamamoto N. Imai H, et al. Among authors: harada h. Anticancer Res. 2013 Aug;33(8):3279-84. Anticancer Res. 2013. PMID: 23898092
Assessment of organ dose reduction and secondary cancer risk associated with the use of proton beam therapy and intensity modulated radiation therapy in treatment of neuroblastomas.
Fuji H, Schneider U, Ishida Y, Konno M, Yamashita H, Kase Y, Murayama S, Onoe T, Ogawa H, Harada H, Asakura H, Nishimura T. Fuji H, et al. Among authors: harada h. Radiat Oncol. 2013 Nov 1;8:255. doi: 10.1186/1748-717X-8-255. Radiat Oncol. 2013. PMID: 24180282 Free PMC article.
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy.
Akamatsu H, Mori K, Naito T, Imai H, Ono A, Shukuya T, Taira T, Kenmotsu H, Murakami H, Endo M, Harada H, Takahashi T, Yamamoto N. Akamatsu H, et al. Among authors: harada h. BMC Cancer. 2014 Jan 14;14:18. doi: 10.1186/1471-2407-14-18. BMC Cancer. 2014. PMID: 24422706 Free PMC article.
Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy.
Imai H, Kaira K, Mori K, Ono A, Akamatsu H, Taira T, Yoshino R, Kenmotsu H, Saitoh J, Harada H, Naito T, Murakami H, Tomizawa Y, Matsuura M, Saito R, Nakajima T, Yamada M, Takahashi T. Imai H, et al. Among authors: harada h. Springerplus. 2015 Mar 31;4:152. doi: 10.1186/s40064-015-0929-3. eCollection 2015. Springerplus. 2015. PMID: 25897409 Free PMC article.
2,624 results